The Huntington’s Disease Society of America (HDSA) has awarded grants totaling more than $2.1 million to support its…
Articles by Marisa Wexler, MS
Eating a high-fiber diet led to improvements in memory and reductions in depression-like behavior in a mouse model of…
A newly launched company known as HD Immune, based in Vienna, is working to develop an antibody treatment…
The Huntington’s Disease Society of America (HDSA) has awarded $898,194 in funding to support six research projects aiming to…
Harness Therapeutics has secured an additional £4 million (about $5 million) in funding, which the U.K. biotech company plans…
Nearly a year of treatment with Neurocrine Biosciences’ Ingrezza (valbenazine) leads to sustained reductions in uncontrolled movements known as…
A four-week titration kit for starting on Austedo (deutetrabenazine) — an approved therapy for chorea, or involuntary muscle contractions,…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SAGE-718, Sage Therapeutics’ experimental oral therapy…
The recent approval in the U.S. of Ingrezza (valbenazine) for adults with Huntington’s disease-associated chorea means patients…
Alternative splicing, a molecular process that’s crucial for genes being “read” to produce proteins, is dysregulated in Huntington’s disease…